Daniel R Kuritzkes

发表

Update of the Drug Resistance Mutations in HIV-1: 2005.

Amalio Telenti, Victoria A Johnson, Francoise Brun-Vezinet, 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Rapid automated cell quantification on HIV microfluidic devices.

Utkan Demirci, Richard L. Lin, Fahim Manzur, 2009, Lab on a chip.

Development of a microfluidic system for measuring HIV-1 viral load

Feng Xu, Utkan Demirci, Altug Akay, 2010, Defense + Commercial Sensing.

DNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics

Anish Vasan, Manoj Kumar Kanakasabapathy, Aparna Sreeram, 2018, Nature Communications.

Update of the drug resistance mutations in HIV-1: Fall 2006.

Deenan Pillay, Victoria A Johnson, Francoise Brun-Vezinet, 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Emerging nanotechnology approaches for HIV / AIDS treatment & prevention Review

Robert Langer, Omid C Farokhzad, Jinjun Shi, 2010 .

Update of the drug resistance mutations in HIV-1: Spring 2008.

Huldrych F Günthard, Deenan Pillay, Victoria A Johnson, 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Efficient on-chip isolation of HIV subtypes.

Utkan Demirci, Fatih Inci, Umut A Gurkan, 2012, Lab on a chip.

Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.

Wei Huang, Rebecca Hoh, Torsten B Neilands, 2007, The Journal of infectious diseases.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Update of the Drug Resistance Mutations in HIV-1: December 2008

Deenan Pillay, Victoria A Johnson, Francoise Brun-Vezinet, 2008 .

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV

Emily B Hanhauser, Emily Hanhauser, Daniel I. S. Rosenbloom, 2016, PLoS pathogens.

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Steven C Johnson, Steven C. Johnson, Daniel R Kuritzkes, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Victoria A Johnson, Daniel R Kuritzkes, Françoise Brun-Vézinet, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug resistance mutations in HIV-1.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2006, JAMA.

Emerging technologies for point-of-care management of HIV infection.

Hadi Shafiee, Utkan Demirci, Fatih Inci, 2015, Annual review of medicine.

Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals

Hulin Wu, Song Yu, Edward P Acosta, 2004, Journal of acquired immune deficiency syndromes.

Update of the drug resistance mutations in HIV-1: Fall 2005.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Viral Dynamics and In Vivo Fitness of HIV-1 in the Presence and Absence of Enfuvirtide

Sebastian Bonhoeffer, Rebecca Hoh, Roger Paredes, 2008, Journal of acquired immune deficiency syndromes.

Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration

Daniel R Kuritzkes, Ruy M Ribeiro, Alan S Perelson, 2017, PLoS pathogens.

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.

Edward P Acosta, Victoria A Johnson, Daniel R Kuritzkes, 2008, The Journal of infectious diseases.

Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).

Mark Holodniy, Robert W Shafer, Daniel R Kuritzkes, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance

Hulin Wu, Edward P Acosta, Daniel R Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood.

Savas Tasoglu, Umut A. Gurkan, Utkan Demirci, 2013, ACS nano.

Assessing resistance costs of antiretroviral therapies via measures of future drug options.

Victor DeGruttola, Hongyu Jiang, David Katzenstein, 2003, The Journal of infectious diseases.

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Eoin Coakley, Robert Gross, Wayne Greaves, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Preventing and managing antiretroviral drug resistance.

Daniel R Kuritzkes, D. Kuritzkes, 2004, AIDS patient care and STDs.

Update of the drug resistance mutations in HIV-1: 2004.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2004, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Effect of the Q207D Mutation in HIV Type 1 Reverse Transcriptase on Zidovudine Susceptibility and Replicative Fitness

Daniel R Kuritzkes, D. Kuritzkes, J. Whitcomb, 2005, Journal of acquired immune deficiency syndromes.

Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis

Rebecca Hoh, Daniel R Kuritzkes, Jeffrey N. Martin, 2006, Journal of acquired immune deficiency syndromes.

Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C.

Sikhulile Moyo, Daniel R Kuritzkes, Shahin Lockman, 2012, Virology.

Quantum dot-based HIV capture and imaging in a microfluidic channel.

Utkan Demirci, Yun-Gon Kim, Sangjun Moon, 2009, Biosensors & bioelectronics.

Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease.

Marc A Suchard, Rebecca Hoh, Daniel R Kuritzkes, 2006, AIDS research and human retroviruses.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Roger Paredes, Victoria A Johnson, Daniel R Kuritzkes, 2010, The Journal of infectious diseases.

Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR.

Sebastien Gallien, Jonathan Z Li, Daniel R Kuritzkes, 2012, Journal of virological methods.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2004, The New England journal of medicine.

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance

Soo-Yon Rhee, Paul Sandstrom, Deenan Pillay, 2007, AIDS.